MEIRAGTX HOLDINGS PLC
MeiraGTx Holdings plc (MGTX) is a clinical‑stage gene therapy company developing treatments for inherited retinal diseases, neurological and metabolic disorders. The group has a diversified pipeline of programmes at various stages, partnerships for research and manufacturing, and a focus on adeno‑associated virus (AAV) delivery platforms. With a market capitalisation of about $744.94M, investors typically monitor trial readouts, regulatory milestones and partnering activity as primary value drivers. As with many biotech companies, MeiraGTx does not have a long track record of commercial revenues and can be dependent on external funding and successful clinical outcomes. Catalysts can produce significant share‑price moves, but trial setbacks, regulatory decisions or capital needs can have the opposite effect. This summary is for educational purposes only and is not personal financial advice; suitability depends on individual circumstances and risk tolerance.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying MEIRAGTX Holdings stock with a target price of $24.14, indicating growth potential.
Financial Health
MEIRAGTX is performing well with strong revenue and healthy profit margins, indicating solid financial health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring MGTX
MASH Biotech Stocks: What's Next After Roche Deal
Roche's acquisition of 89bio for its late-stage liver disease drug highlights a major strategic investment in the MASH treatment space. This move could increase the valuation of other biotech companies developing therapies for metabolic disorders as they become attractive M&A targets.
Published: September 18, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Momentum
Multiple clinical readouts and regulatory milestones can create share‑price catalysts, though individual trials carry binary outcomes and high uncertainty.
Manufacturing & Partnerships
Capabilities and alliances for vector production are strategic strengths, but scaling and quality control can be costly and technically demanding.
Volatility & Funding
Biotech equities are often volatile and may require further capital to advance programmes; investors should be prepared for swings and dilution risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.